Advertisement

Topics

Co-Transcriptional Assembly of Modified RNA Nanoparticles

14:37 EDT 12 Jul 2018 | NIH

The National Cancer Institute seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

The development of nanoparticles as a method of drug delivery is paving the way for precise targeted therapy making it a more attractive and effective method for treating cancer. However, the current methods of designing RNA nanoparticles are limited by three factors: 1) the cost and size limitations associated with chemical synthesis of RNA; 2) the complexity of RNA nanoparticle production; and 3) low retention time of RNA nanoparticles in the patient bloodstream due to their susceptibility to nuclease degradation. 

NCI scientists have developed a method to overcome these challenges in RNA nanoparticle design. The method entails generating RNA nanoparticles having modified nucleotides and/or having increased nuclease resistance where the RNA nanoparticles are formed co-transcriptionally by T7 RNA polymerase in the presence of manganese ions. In essence, the technology results in high-yield production of chemically modified RNA nanoparticles functionalized with siRNAs that are resistant to nucleases from human blood serum

IC: 
NCI
NIH Ref. No.: 
E-223-2012
Advantages: 
  • Reduces the cost and size limitations of solid-phase RNA synthesis.
  • Simplifies production of complex RNA nanoparticles.
  • Increases retention time of RNA nanoparticles.
Applications: 
  • Inexpensive and efficient method of producing chemically modified RNA nanoparticles for diagnostic or therapeutic applications.
Development Status: 

Discovery (Lead Identification)

Updated On: 
Jun 7, 2018
Provider Classifications: 
Publications: 
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
Inventor Lab URL: 
https://irp.nih.gov/pi/bruce-shapiro
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Diagnostics
Therapeutics
DTDT Description: 
Diagnostics
Therapeutics
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing only

Related Invention: 
E-059-2009
E-038-2012
E-039-2012
E Number Only: 
E-223-2012
Inventor First Name: 
Bruce
Kirill
Maria
Mikhail
Inventor Last Name: 
Shapiro
Alfonin
Kireeva
Kashlev

Original Article: Co-Transcriptional Assembly of Modified RNA Nanoparticles

NEXT ARTICLE

More From BioPortfolio on "Co-Transcriptional Assembly of Modified RNA Nanoparticles"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...